Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines [Yahoo! Finance Canada]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance Canada
and administrative expenses of COVID-19 vaccines, its only product on the market. The company has struggled to keep up with the pace of its rivals Moderna and Pfizer, which make messenger RNA-based vaccines compared to its protein-based shot. Novavax reported quarterly sales of $49.8 million for COVID vaccines, down 80.2% from the year earlier. The U.S. company signed a licensing deal worth at least $1.2 billion with French drugmaker Sanofi in May to hand over the rights to sell its vaccines in several markets, including the United States and Europe. Maryland-based Novavax said it would continue to sell the shots in the U.S. during the first half of this year, as it transitions the market to Sanofi beginning with the 2025-2026 vaccination season. It is banking on revenue from its Sanofi deal and vaccines in development, including an experimental COVID-flu combination shot and for bird flu, which is in pre-clinical stage. Novavax said it was eligible to receive royalties in
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Pfizer leads COVID-19 vaccine peers lower after revamped guidance [Seeking Alpha]Seeking Alpha
- New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use [Yahoo! Finance]Yahoo! Finance
- Why I Wouldn't Touch Novavax With a 10-Foot Pole [Yahoo! Finance]Yahoo! Finance
- Novavax (NASDAQ:NVAX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novavax, Inc. (NVAX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 12/15/25 - Form 4
- 11/12/25 - Form SCHEDULE
- 11/6/25 - Form 8-K
- NVAX's page on the SEC website